Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2025 08:00 ET | Source: Alzamend Neuro, Inc.

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Mass. General Hospital; Topline Data by Year-End
May 08, 2025 08:00 ET | Source: Alzamend Neuro, Inc.

Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Announces Reverse Stock Split
May 07, 2025 08:00 ET | Source: Alzamend Neuro, Inc.

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for Its Phase II Clinical Trial of AL001 Study to Take Place at Mass. General Hospital
March 18, 2025 08:00 ET | Source: Alzamend Neuro, Inc.

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for Next-Gen Lithium Treatment of Major Depressive Disorder at Mass. General Hospital
March 11, 2025 08:00 ET | Source: Alzamend Neuro, Inc.

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for AL001 Treatment of Post-Traumatic Stress Disorder at Massachusetts General Hospital
October 27, 2020 06:56 ET | Source: Alzamend Neuro, Inc.

New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression

TAMPA, Fla., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer's Association....
December 26, 2018 09:00 ET | Source: Alzamend Neuro, Inc.

Alzamend Neuro™ Completes New Management Team for 2019

Tampa, Fla., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed top-tier financial executive, Kenneth S. Cragun, CPA, as its...
November 20, 2018 09:00 ET | Source: Alzamend Neuro, Inc.

Alzamend Neuro™ Appoints New CEO, Bio-Pharma Executive Stephan Jackman

Salt Lake City, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed bio-pharma executive, Mr. Stephan Jackman, as its new Chief...